Recruiting Osteogenesis Imperfecta Studies in Milwaukee
A Study of BGB-11417 in Participants With Myeloid Malignancies
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute m...
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durabili...
KRT-232 and TKI Study in Chronic Myeloid Leukemia
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to ...
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). T...
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by c...
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (d...
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have...
About Osteogenesis Imperfecta Clinical Trials in Milwaukee
Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.
There are currently 7 osteogenesis imperfecta clinical trials recruiting participants in Milwaukee, WISCONSIN. These studies are seeking a combined 829 participants. Research is being sponsored by BeiGene, Immunovant Sciences GmbH, Kartos Therapeutics, Inc. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Osteogenesis Imperfecta Clinical Trials in Milwaukee — FAQ
Are there osteogenesis imperfecta clinical trials in Milwaukee?
Yes, there are 7 osteogenesis imperfecta clinical trials currently recruiting in Milwaukee, WISCONSIN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Milwaukee?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Milwaukee research site will contact you about next steps.
Are clinical trials in Milwaukee free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Milwaukee studies also compensate for your time and travel.
What osteogenesis imperfecta treatments are being tested?
The 7 active trials in Milwaukee are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.
Data updated March 2, 2026 from ClinicalTrials.gov